Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Conditions

• Urinary Retention Postoperative

Eligibility Criteria

Sex

ALL

Age

35 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Uroselective alpha-1-adrenergic receptor antagonist — DRUG
  Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
• Placebo — OTHER
  Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)

Study Details

The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.

Key Dates

Start date

Apr 10, 2026

Status verified

Apr 2026

Primary completion

Jan 31, 2027

Completion

Dec 31, 2028

Study Design

Enrollment

20 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Group
  Neurosurgical patients undergoing decompressive laminectomy and/or spinal fusion who will receive uroselective alpha-1-adrenergic receptor antagonist Tamsulosin
• Placebo Comparator: Control Group
  Neurosurgical patients undergoing decompressive laminectomy and/or spinal fusion who will receive a placebo

Primary Outcome Measure

Number of incidences of POUR (Postoperative urinary retention) [ Time Frame: Post-operatively through end of hospital stay, approximately 8-12 days ]

Central Contacts

• Neurologic Surgery Research Team
  507-422-5673

Locations (1)

Find similar trials in Rochester, MN

Related Studies

• Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
  PHASE2 · Recruiting · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania